IRVINE, CA, and HERSTAL, BELGIUM – 27 May 2021 – MDxHealth SA a commercial-stage innovative molecular diagnostics company, held its annual general shareholders’ meeting and an extraordinary general shareholders’ meeting
NEWS RELEASE – REGULATED INFORMATION
27 May 2021, 23:00 p.m. CET
IRVINE, CA, and HERSTAL, BELGIUM – 27 May 2021 – MDxHealth SA (Euronext Brussels: MDXH) (the “Company” or “MDxHealth”) a commercial-stage innovative molecular diagnostics company, today held its annual general shareholders’ meeting (“AGM”) and an extraordinary general shareholders’ meeting (“EGM”)
The items on the agenda of the AGM and EGM included the approval of a number of resolutions relating to the financial year ended on 31 December 2020, as well as the issuance of a new share option plan called the “2021 Share Option Plan” and the renewal of the authorisation to the board of directors to increase the share capital within the framework of the authorised capital. The proposed resolutions that were submitted to the meetings were all duly passed.
The minutes of the AGM and EGM, and documents that were submitted to the meetings can be accessed via the Company’s website.
About MDxHealth®
MDxHealth is a commercial-stage, innovative healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company’s European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit mdxhealth.com and follow us on social media at:
twitter.com/mdxhealth, facebook.com/mdxhealth and linkedin.com/company/mdxhealth.
| For more information: |
| MDxHealth |
| info@mdxhealth.com |
Important information
The MDxHealth logo, MDxHealth, ConfirmMDx and SelectMDx are trademarks or registered trademarks of MDxHealth SA (the “Company” or “MDxHealth”). All other trademarks and service marks are the property of their respective owners.
This announcement contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. You should not place undue reliance on forward-looking statements, which reflect the opinions of MDxHealth only as of the date of this announcement.
Attachment
